Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511861 | 1.00 | PRF1 (0.58) | PRF1ADORA1SLC6A3KDM4EALDH1A1 | |
| SCHEMBL245866 | 0.88 | KDM4E (0.50) | PRF1ADORA1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3303097 | 0.88 | PRF1 (0.46) | PRF1ADORA1SLC6A3KDM4EALDH1A1 | |
| SCHEMBL12534747 | 0.86 | PRF1 (0.50) | PRF1ADORA1SLC6A3KDM4EALDH1A1 | |
| SCHEMBL13929770 | 0.86 | KDM4E (0.52) | PRF1ADORA1SLC6A3KDM4EALDH1A1 | |
| SCHEMBL3338306 | 0.86 | ADORA1 (0.60) | ADORA1KDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL12553020 | 0.86 | ADORA1 (0.56) | PRF1ADORA1SLC6A3KDM4EALDH1A1 | |
| SCHEMBL3359000 | 0.85 | ADORA1 (0.55) | PRF1ADORA1SLC6A3KDM4EADORA2B | |
| SCHEMBL3600737 | 0.85 | KDM4E (0.48) | PRF1ADORA1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL15169500 | 0.84 | KDM4E (0.50) | PRF1ADORA1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2556856-B1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | BAYER IP GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2556831-B1 | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases | BAYER IP GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
| EP-1812430-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007073855-A1 | USE OF ADENOSINE A1 RECEPTOR AGONISTS FOR THE PROTECTION OF RENAL CELLS AGAINST TOXIC EFFECTS CAUSED BY AMINOGLYCOSIDES DURING TREATMENT OF INFECTIOUS DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073855-A1 | USE OF ADENOSINE A1 RECEPTOR AGONISTS FOR THE PROTECTION OF RENAL CELLS AGAINST TOXIC EFFECTS CAUSED BY AMINOGLYCOSIDES DURING TREATMENT OF INFECTIOUS DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | disclosed |
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2006-09-28 | — | — | US | disclosed |
| US-7109218-B2 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2006-09-19 | — | — | US | disclosed |
| WO-2006027142-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| US-20050227972-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1455785-A1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME | Bayer HealthCare AG (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053441-A1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227972-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | TPMT, QDPR, TUBB6 | PRF1 2343/4885ADORA1 998/4885SLC6A3 215/4885 |
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | TPMT, QDPR, TUBB6 | PRF1 2343/4885ADORA1 998/4885SLC6A3 215/4885 |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | PRF1 2680/4885ADORA1 3010/4885SLC6A3 1260/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | PRF1 4579/4885ADORA1 2450/4885SLC6A3 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.